Rosetta Genomics Profile

USD 0.07  19.47%

Rosetta Genomics Summary

Rosetta Genomics Ltd (ROSG) is traded on Nasdaq Capital Markets in USA. It is located in ISRAEL and employs 86 people. Rosetta Genomics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Nano-Cap' category with current market capitalization of 2.73 M. Rosetta Genomics Ltd conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 5.93 M outstanding shares of which 310.26 K shares are at this time shorted by private and institutional investors with about 1.54 trading days to cover. ROSETTA GENOMICS currently holds about 1.32 M in cash with (11.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51 which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Rosetta Genomics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Rosetta Genomics Ltd Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Rosetta Genomics Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 93% 
Equity ratings for Rosetta Genomics Ltd are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Medical Laboratories Research classification in USA and traded on Nasdaq Capital Markets exchange. It employs 86 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRosetta Genomics Ltd
CEO and PresKenneth BerlinAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
Business Address10 Plaut Street
ExchangeNasdaq Capital Markets
IndustryPharmaceutical Products
Contact Number972 73 222 0700
CurrencyUSD - US Dollar

Did you try this?

Run Efficient Frontier Now

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
Hide  View All  NextLaunch Efficient Frontier


Rosetta Genomics Analyst Recommendations
Target PriceAdvice# of Analysts
4.0Strong Buy4Odds
Rosetta Genomics Ltd current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Rosetta Genomics Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Rosetta Genomics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.16March 22, 2017
Rosetta Genomics Ltd normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Rosetta Genomics Corporate Directors
David Sidransky Independent Director
Joshua Rosensweig Director
Tal YaronEldar Independent Director, MBA